Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($0.99), $0.14 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $218.37 million versus the consensus estimate of $221.92 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.